中华皮肤科杂志 ›› 2020, Vol. 53 ›› Issue (9): 754-759.doi: 10.35541/cjd.20190312
李凡 王琳
收稿日期:
2019-02-18
修回日期:
2019-12-16
发布日期:
2020-08-31
通讯作者:
王琳
E-mail:lkzwl@126.com
基金资助:
Li Fan, Wang Lin
Received:
2019-02-18
Revised:
2019-12-16
Published:
2020-08-31
Contact:
Wang Lin
E-mail:lkzwl@126.com
Supported by:
摘要: 【摘要】 皮肤T细胞淋巴瘤(CTCL)是一组具有不同临床表现、病理学改变、免疫表型和分子生物学特征的异质性肿瘤,其发病机制不完全清楚。越来越多的证据表明,肿瘤免疫微环境的组成和功能对于CTCL的发生发展起着重要作用,深入了解其微环境的组成有助于寻找更有效的抗肿瘤免疫治疗方法,同时帮助临床医生更加准确地判断疾病预后。本文就近年来关于CTCL免疫微环境的基础和临床研究进展作一综述。
李凡 王琳. 皮肤T细胞淋巴瘤免疫微环境研究进展[J]. 中华皮肤科杂志, 2020,53(9):754-759. doi:10.35541/cjd.20190312
Li Fan, Wang Lin. Tumor immune microenvironment in cutaneous T-cell lymphoma[J]. Chinese Journal of Dermatology, 2020, 53(9): 754-759.doi:10.35541/cjd.20190312
[1] | Wilcox RA. Cutaneous T⁃cell lymphoma: 2016 update on diagnosis, risk⁃stratification, and management[J]. Am J Hematol, 2016,91(1):151⁃165. doi: 10.1002/ajh.24233. |
[2] | Hanel W, Briski R, Ross CW, et al. A retrospective comparative outcome analysis following systemic therapy in mycosis fungoides and Sézary syndrome[J]. Am J Hematol, 2016,91(12):E491⁃E495. doi: 10.1002/ajh.24564. |
[3] | Lu P, Weaver VM, Werb Z. The extracellular matrix: a dynamic niche in cancer progression[J]. J Cell Biol, 2012,196(4):395⁃406. doi: 10.1083/jcb.201102147. |
[4] | Hsi AC, Lee SJ, Rosman IS, et al. Expression of helper T cell master regulators in inflammatory dermatoses and primary cutaneous T⁃cell lymphomas: diagnostic implications[J]. J Am Acad Dermatol, 2015,72(1):159⁃167. doi: 10.1016/j.jaad.2014.09. 022. |
[5] | Rubio⁃Gonzalez B, Zain J, Rosen ST, et al. Clinical manifestations and pathogenesis of cutaneous lymphomas: current status and future directions[J]. Br J Haematol, 2017,176(1):16⁃36. doi: 10.1111/bjh.14402. |
[6] | Oka T, Sugaya M, Takahashi N, et al. Increased interleukin⁃19 expression in cutaneous T⁃cell lymphoma and atopic dermatitis[J]. Acta Derm Venereol, 2017,97(10):1172⁃1177. doi: 10.2340/ 00015555⁃2723. |
[7] | Nakajima R, Miyagaki T, Hirakawa M, et al. Interleukin⁃25 is involved in cutaneous T⁃cell lymphoma progression by establishing a T helper 2⁃dominant microenvironment[J]. Br J Dermatol, 2018,178(6):1373⁃1382. doi: 10.1111/bjd.16237. |
[8] | Kabasawa M, Sugaya M, Oka T, et al. Decreased interleukin⁃21 expression in skin and blood in advanced mycosis fungoides[J]. J Dermatol, 2016,43(7):819⁃822. doi: 10.1111/1346⁃8138.13278. |
[9] | Kadin ME, Pavlov IY, Delgado JC, et al. High soluble CD30, CD25, and IL⁃6 may identify patients with worse survival in CD30+ cutaneous lymphomas and early mycosis fungoides[J]. J Invest Dermatol, 2012,132(3 Pt 1):703⁃710. doi: 10.1038/jid. 2011.351. |
[10] | Miyagaki T, Sugaya M, Suga H, et al. IL⁃22, but not IL⁃17, dominant environment in cutaneous T⁃cell lymphoma[J]. Clin Cancer Res, 2011,17(24):7529⁃7538. doi: 10.1158/1078⁃0432.CCR⁃11⁃1192. |
[11] | Wang J, Ke XY. The four types of Tregs in malignant lymphomas[J]. J Hematol Oncol, 2011,4:50. doi: 10.1186/1756⁃8722⁃4⁃50. |
[12] | Heid JB, Schmidt A, Oberle N, et al. FOXP3+CD25- tumor cells with regulatory function in Sézary syndrome[J]. J Invest Dermatol, 2009,129(12):2875⁃2885. doi: 10.1038/jid.2009.175. |
[13] | Shareef MM, Elgarhy LH, Rel⁃S W. Expression of granulysin and FOXP3 in cutaneous T cell lymphoma and Sézary syndrome[J]. Asian Pac J Cancer Prev, 2015,16(13):5359⁃5364. doi: 10.7314/apjcp.2015.16.13.5359. |
[14] | Kasper LH, Arnold DL, Coles A J, et al. Lymphocyte subset dynamics following alemtuzumab treatment in patients who relapsed on a prior therapy[J]. J Neuroimmunol, 2014,275(1): 63⁃64. doi:10.1016/j.jneuroim.2014.08.167. |
[15] | Havari E, Turner MJ, Campos⁃Rivera J, et al. Impact of alemtuzumab treatment on the survival and function of human regulatory T cells in vitro[J]. Immunology, 2014,141(1):123⁃131. doi: 10.1111/imm.12178. |
[16] | Watanabe R, Teague JE, Fisher DC, et al. Alemtuzumab therapy for leukemic cutaneous T⁃cell lymphoma: diffuse erythema as a positive predictor of complete remission[J]. JAMA Dermatol, 2014,150(7):776⁃779. doi: 10.1001/jamadermatol.2013.10099. |
[17] | Clark RA, Watanabe R, Teague JE, et al. Skin effector memory T cells do not recirculate and provide immune protection in alemtuzumab⁃treated CTCL patients[J]. Sci Transl Med, 2012,4(117):117ra7. doi: 10.1126/scitranslmed.3003008. |
[18] | Iliadis A, Koletsa T, Patsatsi A, et al. The cellular microenvironment and neoplastic population in mycosis fungoides skin lesions: a clinicopathological correlation[J]. Eur J Dermatol, 2016,26(6):566⁃571. doi: 10.1684/ejd.2016.2847. |
[19] | Carrillo⁃Bustamante P, Keşmir C, de Boer RJ. The evolution of natural killer cell receptors[J]. Immunogenetics, 2016,68(1):3⁃18. doi: 10.1007/s00251⁃015⁃0869⁃7. |
[20] | Schmitt C, Marie⁃Cardine A, Bensussan A. Therapeutic antibodies to KIR3DL2 and other target antigens on cutaneous T⁃cell lymphomas[J]. Front Immunol, 2017,8:1010. doi: 10.3389/fimmu. 2017.01010. |
[21] | Takahashi N, Sugaya M, Suga H, et al. Increased soluble CD226 in sera of patients with cutaneous T⁃cell lymphoma mediates cytotoxic activity against tumor cells via CD155[J]. J Invest Dermatol, 2017,137(8):1766⁃1773. doi: 10.1016/j.jid.2017.03. 025. |
[22] | Accart N, Urosevic⁃Maiwald M, Dummer R, et al. Lymphocytic infiltration in the cutaneous lymphoma microenvironment after injection of TG1042[J]. J Transl Med, 2013,11:226. doi: 10. 1186/1479⁃5876⁃11⁃226. |
[23] | Querfeld C, Rosen ST, Guitart J, et al. Results of an open⁃label multicenter phase 2 trial of lenalidomide monotherapy in refractory mycosis fungoides and Sézary syndrome[J]. Blood, 2014,123(8):1159⁃1166. doi: 10.1182/blood⁃2013⁃09⁃525915. |
[24] | Joyce JA, Fearon DT. T cell exclusion, immune privilege, and the tumor microenvironment[J]. Science, 2015,348(6230):74⁃80. doi: 10.1126/science.aaa6204. |
[25] | Sugaya M, Miyagaki T, Ohmatsu H, et al. Association of the numbers of CD163(+) cells in lesional skin and serum levels of soluble CD163 with disease progression of cutaneous T cell lymphoma[J]. J Dermatol Sci, 2012,68(1):45⁃51. doi: 10.1016/j.jdermsci.2012.07.007. |
[26] | Kim YH, Tavallaee M, Sundram U, et al. Phase II investigator⁃initiated study of brentuximab vedotin in mycosis fungoides and Sézary syndrome with variable CD30 expression level: a multi⁃institution collaborative project[J]. J Clin Oncol, 2015,33(32):3750⁃3758. doi: 10.1200/JCO.2014.60.3969. |
[27] | De Souza A, Tinguely M, Burghart DR, et al. Characterization of the tumor microenvironment in primary cutaneous CD30⁃positive lymphoproliferative disorders: a predominance of CD163⁃positive M2 macrophages[J]. J Cutan Pathol, 2016,43(7):579⁃588. doi: 10.1111/cup.12719. |
[28] | Kakizaki A, Fujimura T, Kambayashi Y, et al. Comparison of CD163+ macrophages and CD206+ cells in lesional skin of CD30+ lymphoproliferative disorders of lymphomatoid papulosis and primary cutaneous anaplastic large⁃cell lymphoma[J]. Acta Derm Venereol, 2015,95(5):600⁃602. doi: 10.2340/0001 5555⁃2016. |
[29] | Litvinov IV, Netchiporouk E, Cordeiro B, et al. The use of transcriptional profiling to improve personalized diagnosis and management of cutaneous T⁃cell lymphoma (CTCL)[J]. Clin Cancer Res, 2015,21(12):2820⁃2829. doi: 10.1158/1078⁃0432.CCR⁃14⁃3322. |
[30] | Wu X, Schulte BC, Zhou Y, et al. Depletion of M2⁃like tumor⁃associated macrophages delays cutaneous T⁃cell lymphoma development in vivo[J]. J Invest Dermatol, 2014,134(11):2814⁃2822. doi: 10.1038/jid.2014.206. |
[31] | Furudate S, Fujimura T, Kakizaki A, et al. Tumor⁃associated M2 macrophages in mycosis fungoides acquire immunomodulatory function by interferon alpha and interferon gamma[J]. J Dermatol Sci, 2016,83(3):182⁃189. doi: 10.1016/j.jdermsci.2016. 05.004. |
[32] | Cannarile MA, Weisser M, Jacob W, et al. Colony⁃stimulating factor 1 receptor (CSF1R) inhibitors in cancer therapy[J]. J Immunother Cancer, 2017,5(1):53. doi: 10.1186/s40425⁃017⁃0257⁃y. |
[33] | Schlapbach C, Ochsenbein A, Kaelin U, et al. High numbers of DC⁃SIGN+ dendritic cells in lesional skin of cutaneous T⁃cell lymphoma[J]. J Am Acad Dermatol, 2010,62(6):995⁃1004. doi: 10.1016/j.jaad.2009.06.082. |
[34] | Zhang QA, Chen ZQ, Chen MH, e t al. The number of regular T cells and immature dendritic cells involved in mycosis fungoides is linked to the tumor stage[J]. Eur Rev Med Pharmacol Sci, 2014,18(4):553⁃558. |
[35] | Vieyra⁃Garcia P, Crouch JD, O′Malley JT, et al. Benign T cells drive clinical skin inflammation in cutaneous T cell lymphoma[J]. JCI Insight, 2019,4(1). pii: 124233. doi: 10.1172/jci.insight. 124233. |
[36] | Deckers J, Hammad H, Hoste E. Langerhans cells: sensing the environment in health and disease[J]. Front Immunol, 2018,9:93. doi: 10.3389/fimmu.2018.00093. |
[37] | Pileri A, Agostinelli C, Sessa M, et al. Langerhans, plasmacytoid dendritic and myeloid⁃derived suppressor cell levels in mycosis fungoides vary according to the stage of the disease[J]. Virchows Arch, 2017,470(5):575⁃582. doi: 10.1007/s00428⁃017⁃2107⁃1. |
[38] | Schwingshackl P, Obermoser G, Nguyen VA, et al. Distribution and maturation of skin dendritic cell subsets in two forms of cutaneous T⁃cell lymphoma: mycosis fungoides and Sézary syndrome[J]. Acta Derm Venereol, 2012,92(3):269⁃275. doi: 10.2340/00015555⁃1220. |
[39] | Müller P, Martin K, Theurich S, et al. Microtubule⁃depolymerizing agents used in antibody⁃drug conjugates induce antitumor immunity by stimulation of dendritic cells[J]. Cancer Immunol Res, 2014,2(8):741⁃755. doi: 10.1158/2326⁃6066.CIR⁃13⁃0198. |
[40] | Rook AH, Gelfand JM, Wysocka M, et al. Topical resiquimod can induce disease regression and enhance T⁃cell effector functions in cutaneous T⁃cell lymphoma[J]. Blood, 2015,126(12):1452⁃1461. doi: 10.1182/blood⁃2015⁃02⁃630335. |
[41] | Motallebnezhad M, Jadidi⁃Niaragh F, Qamsari ES, et al. The immunobiology of myeloid⁃derived suppressor cells in cancer[J]. Tumour Biol, 2016,37(2):1387⁃1406. doi: 10.1007/s13277⁃015⁃4. |
[42] | Geskin LJ, Akilov OE, Kwon S, et al. Therapeutic reduction of cell⁃mediated immunosuppression in mycosis fungoides and Sézary syndrome[J]. Cancer Immunol Immunother, 2018,67(3):423⁃434. doi: 10.1007/s00262⁃017⁃2090⁃z. |
[43] | Bronte V, Brandau S, Chen SH, et al. Recommendations for myeloid⁃derived suppressor cell nomenclature and characterization standards[J]. Nat Commun, 2016,7:12150. doi: 10.1038/ncomms12150. |
[44] | Yu J, Du W, Yan F, et al. Myeloid⁃derived suppressor cells suppress antitumor immune responses through IDO expression and correlate with lymph node metastasis in patients with breast cancer[J]. J Immunol, 2013,190(7):3783⁃3797. doi: 10.4049/jimmunol.1201449. |
[45] | Munn DH, Mellor AL. IDO in the tumor microenvironment: inflammation, counter⁃regulation, and tolerance[J]. Trends Immunol, 2016,37(3):193⁃207. doi: 10.1016/j.it.2016.01.002. |
[46] | Maliniemi P, Laukkanen K, Väkevä L, et al. Biological and clinical significance of tryptophan⁃catabolizing enzymes in cutaneous T⁃cell lymphomas[J]. Oncoimmunology, 2017,6(3):e1273310. doi: 10.1080/2162402X.2016.1273310. |
[47] | Zhang Y, Gallastegui N, Rosenblatt JD. Regulatory B cells in anti⁃tumor immunity[J]. Int Immunol, 2015,27(10):521⁃530. doi: 10.1093/intimm/dxv034. |
[48] | Sarvaria A, Madrigal JA, Saudemont A. B cell regulation in cancer and anti⁃tumor immunity[J]. Cell Mol Immunol, 2017,14(8):662⁃674. doi: 10.1038/cmi.2017.35. |
[49] | Theurich S, Schlaak M, Steguweit H, et al. Targeting tumor⁃infiltrating B cells in cutaneous T⁃cell lymphoma[J]. J Clin Oncol, 2016,34(12):e110⁃116. doi: 10.1200/JCO.2013.50.9471. |
[50] | Eder J, Rogojanu R, Jerney W, et al. Mast cells are abundant in primary cutaneous T⁃cell lymphomas: results from a computer⁃aided quantitative immunohistological study[J/OL]. PLoS One, 2016,11(11):e0163661. doi: 10.1371/journal.pone. 0163661. |
[51] | Miyagaki T, Sugaya M, Suga H, et al. Low herpesvirus entry mediator (HVEM) expression on dermal fibroblasts contributes to a Th2⁃dominant microenvironment in advanced cutaneous T⁃cell lymphoma[J]. J Invest Dermatol, 2012,132(4):1280⁃1289. doi: 10.1038/jid.2011.470. |
[52] | Takahashi N, Sugaya M, Suga H, et al. Thymic stromal chemokine TSLP acts through Th2 cytokine production to induce cutaneous T⁃cell lymphoma[J]. Cancer Res, 2016,76(21):6241⁃6252. doi: 10.1158/0008⁃5472.CAN⁃16⁃0992. |
[1] | 顾安康 张宇 马法库 孔祥君 张理涛. 游泳池肉芽肿56例临床病理分析[J]. 中华皮肤科杂志, 2022, 55(9): 795-798. |
[2] | 唐巧 邓丹琪. 光老化的皮肤影像检查研究进展[J]. 中华皮肤科杂志, 2022, 55(9): 838-840. |
[3] | 祝贺 吴英英 杨蓉娅 王聪敏 敖俊红. 医用冷敷贴缓解海姆泊芬光动力治疗鲜红斑痣术后灼痛及恢复皮肤稳态的疗效观察[J]. 中华皮肤科杂志, 2022, 55(9): 784-789. |
[4] | 赵鹏 秦小卫 秦俊霞 梁丽丽 张馨中 高杰. 白细胞介素18对斑秃患者自然杀伤细胞活性的调控[J]. 中华皮肤科杂志, 2022, 55(9): 778-783. |
[5] | 魏瑾 臧东杰 曾三武 蒋靖 伦文辉. Dowling-Degos病1家系KRT5基因新突变分析[J]. 中华皮肤科杂志, 2022, 55(8): 703-705. |
[6] | 陈文静 邵睿 邹云敏 孟中勤 严翘 宋琳毅 孙建方 陈浩. 黏液表皮样癌8例临床及病理分析[J]. 中华皮肤科杂志, 2022, 55(8): 665-668. |
[7] | 曹淼 崇杉 胡新媛 朱学骏 王明悦. 副肿瘤性天疱疮患者原发肿瘤切除后皮肤黏膜感染及管理分析[J]. 中华皮肤科杂志, 2022, 55(8): 669-675. |
[8] | 晋亮 刘玲. 部分遗传性皮肤病的治疗进展[J]. 中华皮肤科杂志, 2022, 55(8): 735-739. |
[9] | 徐哲. 对遗传性皮肤病的一些思考[J]. 中华皮肤科杂志, 2022, 55(8): 651-652. |
[10] | 刘晨美 陈鸿裕 陈平姣 曾抗 李常兴. 眼皮肤白化病1家系致病基因鉴定[J]. 中华皮肤科杂志, 2022, 55(8): 706-709. |
[11] | 张诗敏 胡赟赟 赵肖庆 杜联军 曹华 郑捷. 影像技术在皮肌炎诊断和病情评估中的研究进展[J]. 中华皮肤科杂志, 2022, 55(7): 637-640. |
[12] | 冯华 高英姝 李清 孙联文. 细胞力学在皮肤科的研究进展[J]. 中华皮肤科杂志, 2022, 55(7): 641-644. |
[13] | 王媛 李志量 李锁 荆可 孙超 梁桂熔 张寒梅 冯素英. 抗p200类天疱疮7例临床及免疫血清学特征分析[J]. 中华皮肤科杂志, 2022, 55(7): 557-561. |
[14] | 施雁庭 黎皓 郑捷 曹华. 程序性细胞死亡蛋白1及其配体通路在特发性炎症性肌病中的研究进展[J]. 中华皮肤科杂志, 2022, 55(7): 633-636. |
[15] | 张宁 李舒 李敬. 免疫检查点抑制剂和靶向药物辅助治疗可切除黑素瘤疗效的网状Meta分析[J]. 中华皮肤科杂志, 2022, 55(7): 603-609. |
|